APO Research
Talk to an analyst

APO RESEARCH · REPORT

Targeting p53 Cancer Therapies

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Targeting p53 Cancer Therapies Industry Growth and Trends Forecast to 2032

22 December 202595 pages

Choose your research edition.

Industry ResearchTargeting p53 Cancer Therapies Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Targeting p53 Cancer Therapies Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Targeting p53 Cancer Therapies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Targeting p53 Cancer Therapies Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Targeting p53 Cancer Therapies Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Targeting p53 Cancer Therapies market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Targeting p53 Cancer Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Targeting p53 Cancer Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Targeting p53 Cancer Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Targeting p53 Cancer Therapies include Alieron Therapeutics, Aprea Therapeutics, Kartos Therapeutics, MultiVir, Rain Oncology, SynerGene Therapeutics, Jc (Wuxi) Company, Sibiono GeneTech and Ascentage Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Targeting p53 Cancer Therapies market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Targeting p53 Cancer Therapies market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Targeting p53 Cancer Therapies market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Targeting p53 Cancer Therapies.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Targeting p53 Cancer Therapies market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Targeting p53 Cancer Therapies Market by Company

Alieron Therapeutics

Aprea Therapeutics

Kartos Therapeutics

MultiVir

Rain Oncology

SynerGene Therapeutics

Jc (Wuxi) Company

Sibiono GeneTech

Ascentage Pharma

Targeting p53 Cancer Therapies Segment by Type

Gene Therapy

Immunotherapy

Small Molecule Drugs

Others

Targeting p53 Cancer Therapies Segment by Application

Hospital

Clinic

Others

Targeting p53 Cancer Therapies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeting p53 Cancer Therapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Targeting p53 Cancer Therapies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeting p53 Cancer Therapies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Targeting p53 Cancer Therapies manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Targeting p53 Cancer Therapies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Gene Therapy Table 2. Major Company of Immunotherapy Table 3. Major Company of Small Molecule Drugs Table 4. Major Company of Others Table 5. Global Targeting p53 Cancer Therapies Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Targeting p53 Cancer Therapies Sales by Type (2021-2026) & (k units) Table 7. Global Targeting p53 Cancer Therapies Sales Market Share in Volume by Type (2021-2026) Table 8. Global Targeting p53 Cancer Therapies Sales by Type (2021-2026) & (US$ Million) Table 9. Global Targeting p53 Cancer Therapies Sales Market Share in Value by Type (2021-2026) Table 10. Global Targeting p53 Cancer Therapies Price by Type (2021-2026) & (US$/unit) Table 11. Global Targeting p53 Cancer Therapies Sales by Type (2027-2032) & (k units) Table 12. Global Targeting p53 Cancer Therapies Sales Market Share in Volume by Type (2027-2032) Table 13. Global Targeting p53 Cancer Therapies Sales by Type (2027-2032) & (US$ Million) Table 14. Global Targeting p53 Cancer Therapies Sales Market Share in Value by Type (2027-2032) Table 15. Global Targeting p53 Cancer Therapies Price by Type (2027-2032) & (US$/unit) Table 16. North America Targeting p53 Cancer Therapies Sales by Type (2021-2026) & (k units) Table 17. North America Targeting p53 Cancer Therapies Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Targeting p53 Cancer Therapies Sales by Type (2021-2026) & (k units) Table 19. Europe Targeting p53 Cancer Therapies Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Targeting p53 Cancer Therapies Sales by Type (2021-2026) & (k units) Table 21. Asia-Pacific Targeting p53 Cancer Therapies Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Targeting p53 Cancer Therapies Sales by Type (2021-2026) & (k units) Table 23. Latin America Targeting p53 Cancer Therapies Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Targeting p53 Cancer Therapies Sales by Type (2021-2026) & (k units) Table 25. Middle East and Africa Targeting p53 Cancer Therapies Sales by Type (2021-2026) & (US$ Million) Table 26. Targeting p53 Cancer Therapies Industry Trends Table 27. Targeting p53 Cancer Therapies Industry Drivers Table 28. Targeting p53 Cancer Therapies Industry Opportunities and Challenges Table 29. Targeting p53 Cancer Therapies Industry Restraints Table 30. Global Targeting p53 Cancer Therapies Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Targeting p53 Cancer Therapies Revenue Market Share by Company (2021-2026) Table 32. Global Targeting p53 Cancer Therapies Sales by Company (2021-2026) & (k units) Table 33. Global Targeting p53 Cancer Therapies Sales Share by Company (2021-2026) Table 34. Global Targeting p53 Cancer Therapies Market Price by Company (2021-2026) & (US$/unit) Table 35. Global Targeting p53 Cancer Therapies Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Targeting p53 Cancer Therapies Major Company Production Sites and Headquarters Table 37. Global Targeting p53 Cancer Therapies Company, Product Type & Application Table 38. Global Targeting p53 Cancer Therapies Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Targeting p53 Cancer Therapies by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Targeting p53 Cancer Therapies Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Targeting p53 Cancer Therapies Sales by Region (2021-2026) & (k units) Table 43. Global Targeting p53 Cancer Therapies Sales Market Share in Volume by Region (2021-2026) Table 44. Global Targeting p53 Cancer Therapies Sales by Region (2021-2026) & (US$ Million) Table 45. Global Targeting p53 Cancer Therapies Sales Market Share in Value by Region (2021-2026) Table 46. Global Targeting p53 Cancer Therapies Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 47. Global Targeting p53 Cancer Therapies Sales by Region (2027-2032) & (k units) Table 48. Global Targeting p53 Cancer Therapies Sales Market Share in Volume by Region (2027-2032) Table 49. Global Targeting p53 Cancer Therapies Sales by Region (2027-2032) & (US$ Million) Table 50. Global Targeting p53 Cancer Therapies Sales Market Share in Value by Region (2027-2032) Table 51. Global Targeting p53 Cancer Therapies Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 52. Global Targeting p53 Cancer Therapies Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Targeting p53 Cancer Therapies Sales by Application (2021-2026) & (k units) Table 54. Global Targeting p53 Cancer Therapies Sales Market Share in Volume by Application (2021-2026) Table 55. Global Targeting p53 Cancer Therapies Sales by Application (2021-2026) & (US$ Million) Table 56. Global Targeting p53 Cancer Therapies Sales Market Share in Value by Application (2021-2026) Table 57. Global Targeting p53 Cancer Therapies Price by Application (2021-2026) & (US$/unit) Table 58. Global Targeting p53 Cancer Therapies Sales by Application (2027-2032) & (k units) Table 59. Global Targeting p53 Cancer Therapies Sales Market Share in Volume by Application (2027-2032) Table 60. Global Targeting p53 Cancer Therapies Sales by Application (2027-2032) & (US$ Million) Table 61. Global Targeting p53 Cancer Therapies Sales Market Share in Value by Application (2027-2032) Table 62. Global Targeting p53 Cancer Therapies Price by Application (2027-2032) & (US$/unit) Table 63. North America Targeting p53 Cancer Therapies Sales by Application (2021-2026) & (k units) Table 64. North America Targeting p53 Cancer Therapies Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Targeting p53 Cancer Therapies Sales by Application (2021-2026) & (k units) Table 66. Europe Targeting p53 Cancer Therapies Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Targeting p53 Cancer Therapies Sales by Application (2021-2026) & (k units) Table 68. Asia-Pacific Targeting p53 Cancer Therapies Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Targeting p53 Cancer Therapies Sales by Application (2021-2026) & (k units) Table 70. Latin America Targeting p53 Cancer Therapies Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Targeting p53 Cancer Therapies Sales by Application (2021-2026) & (k units) Table 72. Middle East and Africa Targeting p53 Cancer Therapies Sales by Application (2021-2026) & (US$ Million) Table 73. Alieron Therapeutics Company Information Table 74. Alieron Therapeutics Business Overview Table 75. Alieron Therapeutics Targeting p53 Cancer Therapies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Alieron Therapeutics Targeting p53 Cancer Therapies Product Portfolio Table 77. Alieron Therapeutics Recent Development Table 78. Aprea Therapeutics Company Information Table 79. Aprea Therapeutics Business Overview Table 80. Aprea Therapeutics Targeting p53 Cancer Therapies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Aprea Therapeutics Targeting p53 Cancer Therapies Product Portfolio Table 82. Aprea Therapeutics Recent Development Table 83. Kartos Therapeutics Company Information Table 84. Kartos Therapeutics Business Overview Table 85. Kartos Therapeutics Targeting p53 Cancer Therapies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Kartos Therapeutics Targeting p53 Cancer Therapies Product Portfolio Table 87. Kartos Therapeutics Recent Development Table 88. MultiVir Company Information Table 89. MultiVir Business Overview Table 90. MultiVir Targeting p53 Cancer Therapies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. MultiVir Targeting p53 Cancer Therapies Product Portfolio Table 92. MultiVir Recent Development Table 93. Rain Oncology Company Information Table 94. Rain Oncology Business Overview Table 95. Rain Oncology Targeting p53 Cancer Therapies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Rain Oncology Targeting p53 Cancer Therapies Product Portfolio Table 97. Rain Oncology Recent Development Table 98. SynerGene Therapeutics Company Information Table 99. SynerGene Therapeutics Business Overview Table 100. SynerGene Therapeutics Targeting p53 Cancer Therapies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. SynerGene Therapeutics Targeting p53 Cancer Therapies Product Portfolio Table 102. SynerGene Therapeutics Recent Development Table 103. Jc (Wuxi) Company Company Information Table 104. Jc (Wuxi) Company Business Overview Table 105. Jc (Wuxi) Company Targeting p53 Cancer Therapies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Jc (Wuxi) Company Targeting p53 Cancer Therapies Product Portfolio Table 107. Jc (Wuxi) Company Recent Development Table 108. Sibiono GeneTech Company Information Table 109. Sibiono GeneTech Business Overview Table 110. Sibiono GeneTech Targeting p53 Cancer Therapies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Sibiono GeneTech Targeting p53 Cancer Therapies Product Portfolio Table 112. Sibiono GeneTech Recent Development Table 113. Ascentage Pharma Company Information Table 114. Ascentage Pharma Business Overview Table 115. Ascentage Pharma Targeting p53 Cancer Therapies Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Ascentage Pharma Targeting p53 Cancer Therapies Product Portfolio Table 117. Ascentage Pharma Recent Development Table 118. North America Targeting p53 Cancer Therapies Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 119. North America Targeting p53 Cancer Therapies Sales by Country (2021-2026) & (k units) Table 120. North America Targeting p53 Cancer Therapies Sales Market Share by Country (2021-2026) Table 121. North America Targeting p53 Cancer Therapies Sales Forecast by Country (2027-2032) & (k units) Table 122. North America Targeting p53 Cancer Therapies Sales Market Share Forecast by Country (2027-2032) Table 123. North America Targeting p53 Cancer Therapies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 124. North America Targeting p53 Cancer Therapies Market Size by Country (2021-2026) & (US$ Million) Table 125. North America Targeting p53 Cancer Therapies Market Share by Country (2021-2026) Table 126. North America Targeting p53 Cancer Therapies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 127. North America Targeting p53 Cancer Therapies Market Share Forecast by Country (2027-2032) Table 128. Europe Targeting p53 Cancer Therapies Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 129. Europe Targeting p53 Cancer Therapies Sales by Country (2021-2026) & (k units) Table 130. Europe Targeting p53 Cancer Therapies Sales Market Share by Country (2021-2026) Table 131. Europe Targeting p53 Cancer Therapies Sales Forecast by Country (2027-2032) & (k units) Table 132. Europe Targeting p53 Cancer Therapies Sales Market Share Forecast by Country (2027-2032) Table 133. Europe Targeting p53 Cancer Therapies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. Europe Targeting p53 Cancer Therapies Market Size by Country (2021-2026) & (US$ Million) Table 135. Europe Targeting p53 Cancer Therapies Market Share by Country (2021-2026) Table 136. Europe Targeting p53 Cancer Therapies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. Europe Targeting p53 Cancer Therapies Market Share Forecast by Country (2027-2032) Table 138. Asia-Pacific Targeting p53 Cancer Therapies Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 139. Asia-Pacific Targeting p53 Cancer Therapies Sales by Country (2021-2026) & (k units) Table 140. Asia-Pacific Targeting p53 Cancer Therapies Sales Market Share by Country (2021-2026) Table 141. Asia-Pacific Targeting p53 Cancer Therapies Sales Forecast by Country (2027-2032) & (k units) Table 142. Asia-Pacific Targeting p53 Cancer Therapies Sales Market Share Forecast by Country (2027-2032) Table 143. Asia-Pacific Targeting p53 Cancer Therapies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Asia-Pacific Targeting p53 Cancer Therapies Market Size by Country (2021-2026) & (US$ Million) Table 145. Asia-Pacific Targeting p53 Cancer Therapies Market Share by Country (2021-2026) Table 146. Asia-Pacific Targeting p53 Cancer Therapies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Asia-Pacific Targeting p53 Cancer Therapies Market Share Forecast by Country (2027-2032) Table 148. Latin America Targeting p53 Cancer Therapies Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 149. Latin America Targeting p53 Cancer Therapies Sales by Country (2021-2026) & (k units) Table 150. Latin America Targeting p53 Cancer Therapies Sales Market Share by Country (2021-2026) Table 151. Latin America Targeting p53 Cancer Therapies Sales Forecast by Country (2027-2032) & (k units) Table 152. Latin America Targeting p53 Cancer Therapies Sales Market Share Forecast by Country (2027-2032) Table 153. Latin America Targeting p53 Cancer Therapies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Latin America Targeting p53 Cancer Therapies Market Size by Country (2021-2026) & (US$ Million) Table 155. Latin America Targeting p53 Cancer Therapies Market Share by Country (2021-2026) Table 156. Latin America Targeting p53 Cancer Therapies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Latin America Targeting p53 Cancer Therapies Market Share Forecast by Country (2027-2032) Table 158. Middle East and Africa Targeting p53 Cancer Therapies Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 159. Middle East and Africa Targeting p53 Cancer Therapies Sales by Country (2021-2026) & (k units) Table 160. Middle East and Africa Targeting p53 Cancer Therapies Sales Market Share by Country (2021-2026) Table 161. Middle East and Africa Targeting p53 Cancer Therapies Sales Forecast by Country (2027-2032) & (k units) Table 162. Middle East and Africa Targeting p53 Cancer Therapies Sales Market Share Forecast by Country (2027-2032) Table 163. Middle East and Africa Targeting p53 Cancer Therapies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Middle East and Africa Targeting p53 Cancer Therapies Market Size by Country (2021-2026) & (US$ Million) Table 165. Middle East and Africa Targeting p53 Cancer Therapies Market Share by Country (2021-2026) Table 166. Middle East and Africa Targeting p53 Cancer Therapies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Middle East and Africa Targeting p53 Cancer Therapies Market Share Forecast by Country (2027-2032) Table 168. Key Raw Materials Table 169. Raw Materials Key Suppliers Table 170. Targeting p53 Cancer Therapies Distributors List Table 171. Targeting p53 Cancer Therapies Customers List Table 172. Research Programs/Design for This Report Table 173. Authors List of This Report Table 174. Secondary Sources Table 175. Primary Sources List of Figures Figure 1. Targeting p53 Cancer Therapies Image Figure 2. Global Targeting p53 Cancer Therapies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Targeting p53 Cancer Therapies Market Size (2021-2032) & (US$ Million) Figure 4. Global Targeting p53 Cancer Therapies Sales (2021-2032) & (k units) Figure 5. Gene Therapy Image Figure 6. Global Gene Therapy Sales YoY Growth (2021-2032) & (k units) Figure 7. Immunotherapy Image Figure 8. Global Immunotherapy Sales YoY Growth (2021-2032) & (k units) Figure 9. Small Molecule Drugs Image Figure 10. Global Small Molecule Drugs Sales YoY Growth (2021-2032) & (k units) Figure 11. Others Image Figure 12. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 13. Global Targeting p53 Cancer Therapies Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Targeting p53 Cancer Therapies Market Share by Type 2025 VS 2032 Figure 15. North America Targeting p53 Cancer Therapies Sales Market Share in Volume by Type in 2025 Figure 16. North America Targeting p53 Cancer Therapies Sales Market Share in Value by Type in 2025 Figure 17. Europe Targeting p53 Cancer Therapies Sales Market Share in Volume by Type in 2025 Figure 18. Europe Targeting p53 Cancer Therapies Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Targeting p53 Cancer Therapies Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Targeting p53 Cancer Therapies Sales Market Share in Value by Type in 2025 Figure 21. Latin America Targeting p53 Cancer Therapies Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Targeting p53 Cancer Therapies Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Targeting p53 Cancer Therapies Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Targeting p53 Cancer Therapies Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Targeting p53 Cancer Therapies Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Hospital Image Figure 28. Global Hospital Sales YoY Growth (2021-2032) & (k units) Figure 29. Clinic Image Figure 30. Global Clinic Sales YoY Growth (2021-2032) & (k units) Figure 31. Others Image Figure 32. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 33. Global Targeting p53 Cancer Therapies Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Targeting p53 Cancer Therapies Market Share by Application 2025 VS 2032 Figure 35. North America Targeting p53 Cancer Therapies Sales Market Share in Volume by Application in 2025 Figure 36. North America Targeting p53 Cancer Therapies Sales Market Share in Value by Application in 2025 Figure 37. Europe Targeting p53 Cancer Therapies Sales Market Share in Volume by Application in 2025 Figure 38. Europe Targeting p53 Cancer Therapies Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Targeting p53 Cancer Therapies Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Targeting p53 Cancer Therapies Sales Market Share in Value by Application in 2025 Figure 41. Latin America Targeting p53 Cancer Therapies Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Targeting p53 Cancer Therapies Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Targeting p53 Cancer Therapies Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Targeting p53 Cancer Therapies Sales Market Share in Value by Application in 2025 Figure 45. North America Targeting p53 Cancer Therapies Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. North America Targeting p53 Cancer Therapies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Targeting p53 Cancer Therapies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Targeting p53 Cancer Therapies Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Targeting p53 Cancer Therapies Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Europe Targeting p53 Cancer Therapies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Targeting p53 Cancer Therapies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Targeting p53 Cancer Therapies Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Targeting p53 Cancer Therapies Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Asia-Pacific Targeting p53 Cancer Therapies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Targeting p53 Cancer Therapies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Targeting p53 Cancer Therapies Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Targeting p53 Cancer Therapies Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Latin America Targeting p53 Cancer Therapies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Targeting p53 Cancer Therapies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Targeting p53 Cancer Therapies Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Targeting p53 Cancer Therapies Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 62. Middle East and Africa Targeting p53 Cancer Therapies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Targeting p53 Cancer Therapies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Targeting p53 Cancer Therapies Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Targeting p53 Cancer Therapies Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Targeting p53 Cancer Therapies Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Gene Therapy
  • Immunotherapy
  • Small Molecule Drugs
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Alieron Therapeutics
  • Aprea Therapeutics
  • Kartos Therapeutics
  • MultiVir
  • Rain Oncology
  • SynerGene Therapeutics
  • Jc (Wuxi) Company
  • Sibiono GeneTech
  • Ascentage Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Targeting p53 Cancer Therapies Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Targeting p53 Cancer Therapies Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Targeting p53 Cancer Therapies Market by Type
  6. 1.3.1 Gene Therapy
  7. 1.3.2 Immunotherapy
  8. 1.3.3 Small Molecule Drugs
  9. 1.3.4 Others
  10. 1.4 Global Targeting p53 Cancer Therapies Market Size by Type
  11. 1.4.1 Global Targeting p53 Cancer Therapies Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Targeting p53 Cancer Therapies Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Targeting p53 Cancer Therapies Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Targeting p53 Cancer Therapies Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Targeting p53 Cancer Therapies Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Targeting p53 Cancer Therapies Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Targeting p53 Cancer Therapies Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Targeting p53 Cancer Therapies Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Targeting p53 Cancer Therapies Industry Trends
  2. 2.2 Targeting p53 Cancer Therapies Industry Drivers
  3. 2.3 Targeting p53 Cancer Therapies Industry Opportunities and Challenges
  4. 2.4 Targeting p53 Cancer Therapies Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Targeting p53 Cancer Therapies Revenue (2021-2026)
  2. 3.2 Global Top Players by Targeting p53 Cancer Therapies Sales (2021-2026)
  3. 3.3 Global Top Players by Targeting p53 Cancer Therapies Price (2021-2026)
  4. 3.4 Global Targeting p53 Cancer Therapies Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Targeting p53 Cancer Therapies Major Company Production Sites & Headquarters
  6. 3.6 Global Targeting p53 Cancer Therapies Company, Product Type & Application
  7. 3.7 Global Targeting p53 Cancer Therapies Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Targeting p53 Cancer Therapies Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Targeting p53 Cancer Therapies Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Targeting p53 Cancer Therapies Tier 1, Tier 2, and Tier 3
4 Targeting p53 Cancer Therapies Regional Status and Outlook
  1. 4.1 Global Targeting p53 Cancer Therapies Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Targeting p53 Cancer Therapies Historic Market Size by Region
  3. 4.2.1 Global Targeting p53 Cancer Therapies Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Targeting p53 Cancer Therapies Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Targeting p53 Cancer Therapies Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Targeting p53 Cancer Therapies Forecasted Market Size by Region
  7. 4.3.1 Global Targeting p53 Cancer Therapies Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Targeting p53 Cancer Therapies Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Targeting p53 Cancer Therapies Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Targeting p53 Cancer Therapies by Application
  1. 5.1 Targeting p53 Cancer Therapies Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Targeting p53 Cancer Therapies Market Size by Application
  6. 5.2.1 Global Targeting p53 Cancer Therapies Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Targeting p53 Cancer Therapies Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Targeting p53 Cancer Therapies Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Targeting p53 Cancer Therapies Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Targeting p53 Cancer Therapies Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Targeting p53 Cancer Therapies Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Targeting p53 Cancer Therapies Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Targeting p53 Cancer Therapies Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Alieron Therapeutics
  2. 6.1.1 Alieron Therapeutics Company Information
  3. 6.1.2 Alieron Therapeutics Business Overview
  4. 6.1.3 Alieron Therapeutics Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Alieron Therapeutics Targeting p53 Cancer Therapies Product Portfolio
  6. 6.1.5 Alieron Therapeutics Recent Developments
  7. 6.2 Aprea Therapeutics
  8. 6.2.1 Aprea Therapeutics Company Information
  9. 6.2.2 Aprea Therapeutics Business Overview
  10. 6.2.3 Aprea Therapeutics Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Aprea Therapeutics Targeting p53 Cancer Therapies Product Portfolio
  12. 6.2.5 Aprea Therapeutics Recent Developments
  13. 6.3 Kartos Therapeutics
  14. 6.3.1 Kartos Therapeutics Company Information
  15. 6.3.2 Kartos Therapeutics Business Overview
  16. 6.3.3 Kartos Therapeutics Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Kartos Therapeutics Targeting p53 Cancer Therapies Product Portfolio
  18. 6.3.5 Kartos Therapeutics Recent Developments
  19. 6.4 MultiVir
  20. 6.4.1 MultiVir Company Information
  21. 6.4.2 MultiVir Business Overview
  22. 6.4.3 MultiVir Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 MultiVir Targeting p53 Cancer Therapies Product Portfolio
  24. 6.4.5 MultiVir Recent Developments
  25. 6.5 Rain Oncology
  26. 6.5.1 Rain Oncology Company Information
  27. 6.5.2 Rain Oncology Business Overview
  28. 6.5.3 Rain Oncology Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Rain Oncology Targeting p53 Cancer Therapies Product Portfolio
  30. 6.5.5 Rain Oncology Recent Developments
  31. 6.6 SynerGene Therapeutics
  32. 6.6.1 SynerGene Therapeutics Company Information
  33. 6.6.2 SynerGene Therapeutics Business Overview
  34. 6.6.3 SynerGene Therapeutics Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 SynerGene Therapeutics Targeting p53 Cancer Therapies Product Portfolio
  36. 6.6.5 SynerGene Therapeutics Recent Developments
  37. 6.7 Jc (Wuxi) Company
  38. 6.7.1 Jc (Wuxi) Company Company Information
  39. 6.7.2 Jc (Wuxi) Company Business Overview
  40. 6.7.3 Jc (Wuxi) Company Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Jc (Wuxi) Company Targeting p53 Cancer Therapies Product Portfolio
  42. 6.7.5 Jc (Wuxi) Company Recent Developments
  43. 6.8 Sibiono GeneTech
  44. 6.8.1 Sibiono GeneTech Company Information
  45. 6.8.2 Sibiono GeneTech Business Overview
  46. 6.8.3 Sibiono GeneTech Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Sibiono GeneTech Targeting p53 Cancer Therapies Product Portfolio
  48. 6.8.5 Sibiono GeneTech Recent Developments
  49. 6.9 Ascentage Pharma
  50. 6.9.1 Ascentage Pharma Company Information
  51. 6.9.2 Ascentage Pharma Business Overview
  52. 6.9.3 Ascentage Pharma Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Ascentage Pharma Targeting p53 Cancer Therapies Product Portfolio
  54. 6.9.5 Ascentage Pharma Recent Developments
7 North America by Country
  1. 7.1 North America Targeting p53 Cancer Therapies Sales by Country
  2. 7.1.1 North America Targeting p53 Cancer Therapies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Targeting p53 Cancer Therapies Sales by Country (2021-2026)
  4. 7.1.3 North America Targeting p53 Cancer Therapies Sales Forecast by Country (2027-2032)
  5. 7.2 North America Targeting p53 Cancer Therapies Market Size by Country
  6. 7.2.1 North America Targeting p53 Cancer Therapies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Targeting p53 Cancer Therapies Market Size by Country (2021-2026)
  8. 7.2.3 North America Targeting p53 Cancer Therapies Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Targeting p53 Cancer Therapies Sales by Country
  2. 8.1.1 Europe Targeting p53 Cancer Therapies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Targeting p53 Cancer Therapies Sales by Country (2021-2026)
  4. 8.1.3 Europe Targeting p53 Cancer Therapies Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Targeting p53 Cancer Therapies Market Size by Country
  6. 8.2.1 Europe Targeting p53 Cancer Therapies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Targeting p53 Cancer Therapies Market Size by Country (2021-2026)
  8. 8.2.3 Europe Targeting p53 Cancer Therapies Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Targeting p53 Cancer Therapies Sales by Country
  2. 9.1.1 Asia-Pacific Targeting p53 Cancer Therapies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Targeting p53 Cancer Therapies Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Targeting p53 Cancer Therapies Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Targeting p53 Cancer Therapies Market Size by Country
  6. 9.2.1 Asia-Pacific Targeting p53 Cancer Therapies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Targeting p53 Cancer Therapies Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Targeting p53 Cancer Therapies Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Targeting p53 Cancer Therapies Sales by Country
  2. 10.1.1 South America Targeting p53 Cancer Therapies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Targeting p53 Cancer Therapies Sales by Country (2021-2026)
  4. 10.1.3 South America Targeting p53 Cancer Therapies Sales Forecast by Country (2027-2032)
  5. 10.2 South America Targeting p53 Cancer Therapies Market Size by Country
  6. 10.2.1 South America Targeting p53 Cancer Therapies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Targeting p53 Cancer Therapies Market Size by Country (2021-2026)
  8. 10.2.3 South America Targeting p53 Cancer Therapies Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Targeting p53 Cancer Therapies Sales by Country
  2. 11.1.1 Middle East and Africa Targeting p53 Cancer Therapies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Targeting p53 Cancer Therapies Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Targeting p53 Cancer Therapies Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Targeting p53 Cancer Therapies Market Size by Country
  6. 11.2.1 Middle East and Africa Targeting p53 Cancer Therapies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Targeting p53 Cancer Therapies Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Targeting p53 Cancer Therapies Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Targeting p53 Cancer Therapies Value Chain Analysis
  2. 12.1.1 Targeting p53 Cancer Therapies Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Targeting p53 Cancer Therapies Production Mode & Process
  7. 12.2 Targeting p53 Cancer Therapies Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Targeting p53 Cancer Therapies Distributors
  10. 12.2.3 Targeting p53 Cancer Therapies Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst